Literature DB >> 27365198

Improved survival associated with a balanced structure between adenomatous and squamous components in patients with adenosquamous carcinoma of the lung.

H Zhao1, H Yang2, F Yao3, Y Sun3, J Xu4, H Gu3, Z Shen5.   

Abstract

BACKGROUND: Primary adenosquamous carcinoma (ASC) of the lung is rare and its biological behavior has not yet been thoroughly described. The aim of this study was to analyze the clinicopathological characteristics and prognostic factors associated with ASC. MATERIALS: Clinical records of patients with ASC of the lung who underwent surgery between October 2008 and December 2014 in a single institution were retrospectively reviewed.
RESULTS: A total of 205 patients were identified. Patients with balanced structural components had significantly better prognosis than those with squamous (p = 0.014) or adenomatous (p < 0.001) predominance, and those with N0, N1, and N2 ASC (N0 vs. N1 [ p = 0.031] and N1 vs. N2 [p = 0.037], respectively), or stage I, II and IIIA ASC (stage I vs. II [p = 0.021] and stage II vs. IIIA [p = 0.007], respectively) had significant differences with respect to overall survival (OS). Multivariate analysis identified structural components (p = 0.011), tumor, node and metastasis (TNM) status (p < 0.001), and adjuvant chemotherapy (p = 0.008) as significantly prognostic factors for OS, and structural components (p = 0.030), TNM stage (p < 0.001) and adjuvant chemotherapy (p = 0.005) as the corresponding variables for disease-free survival.
CONCLUSIONS: A balanced structure between adenomatous and squamous components in patients with primary ASC of the lung was associated with better prognosis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenosquamous lung carcinoma; Surgery; Survival

Mesh:

Year:  2016        PMID: 27365198     DOI: 10.1016/j.ejso.2016.05.009

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  Risk factors of postoperative recurrence and potential candidate of adjuvant radiotherapy in lung adenosquamous carcinoma.

Authors:  Jianjiao Ni; Zhiqin Zheng; Juan Li; Yuan Li; Min Fan; Liang Liu
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

2.  Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma.

Authors:  Yangli Liu; Ying Zhu; Lihong Bai; Fengjia Chen; Jue Wang; Yubiao Guo
Journal:  BMC Cancer       Date:  2020-06-05       Impact factor: 4.430

3.  Tumor Location and Survival Outcomes in Lung Adenosquamous Carcinoma: A Propensity Score Matched Analysis.

Authors:  Xinlin Shi; Xiangrong Shao; Yawen Zhang; Feng Wu; Yujian Tao
Journal:  Med Sci Monit       Date:  2020-07-02

Review 4.  Research progress of the clinicopathologic features of lung adenosquamous carcinoma.

Authors:  Jing Wang; Yanling Wang; Mengting Tong; Hongming Pan; Da Li
Journal:  Onco Targets Ther       Date:  2018-10-16       Impact factor: 4.147

5.  Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma.

Authors:  Chao Zhang; Haitang Yang; Baoping Lang; Xiangdong Yu; Peng Xiao; Dian Zhang; Liwen Fan; Xiao Zhang
Journal:  Cancer Manag Res       Date:  2018-08-02       Impact factor: 3.989

6.  Survival analysis for lung adenosquamous carcinoma patients with brain metastasis.

Authors:  Feng Pan; Shaohua Cui; Weimin Wang; Aiqin Gu; Liyan Jiang
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

7.  An Uncommon Lung Neoplasm in a Young Patient: Diagnostic Challenges.

Authors:  Felipe Saceanu Leser; Lucas Dalsenter Romano; Kauê Ruan de Resende; José Roberto Lapa E Silva
Journal:  Am J Case Rep       Date:  2020-10-16

8.  A nomogram to predict prognosis of patients with lung adenosquamous carcinoma: a population-based study.

Authors:  Jiaqi Liang; Qihai Sui; Yuansheng Zheng; Guoshu Bi; Zhencong Chen; Ming Li; Yiwei Huang; Tao Lu; Cheng Zhan; Weigang Guo
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

Review 9.  Adenosquamous carcinoma of the lung.

Authors:  Chenghui Li; Hongyang Lu
Journal:  Onco Targets Ther       Date:  2018-08-14       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.